AusBiotech has announced the release of its 2023-2024 Annual Report, showcasing a year of strong member engagement and sector enablement.
CEO Rebekah Cassidy said the report demonstrates the continued commitment of AuBiotech and its Board to support members across the life sciences value chain.
“AusBiotech continues to be Australia's leading national and global advocate for life sciences, working to help its more than 3000 members thrive by shaping policy, creating connections, and fostering knowledge sharing.
“In the 2023–2024 financial year under the leadership of our former CEO, Lorraine Maxwell, and then Acting CEO, Rosanne Hyland, AusBiotech spearheaded key initiatives, engaging with government and industry leaders while connecting nearly 6,500 people through a series of nationwide events.”
Notable achievements included advocacy for the Clinical Trials One Stop Shop and sustainable funding models for the TGA. The organisation held several state-based policy roundtables with members, a CEO Policy Forum in Canberra, and the BIO 2024 Investing in Australia Roundtable.
“Building upon AusBiotech's exceptional heritage and stepping into the footsteps of prior strong leaders has been a privilege. As CEO, I have witnessed first-hand the expertise within our membership that is poised to drive Australia's life sciences sector forward.
“Having spent my first few months as CEO listening deeply to our members, policy makers and a range of leaders across the sector, there’s no doubt in my mind that life sciences, and in particular biotech and medtech, can and should be an important part of a modern and diversified Australian economy. How we build collective and cohesive voice to enable that outcome will be core to our strategic agenda moving forward.”
"I am grateful to our hardworking AusBiotech team and our dedicated Board for delivering the critical work represented in our 2023 – 2024 Annual Report."